


Milbank

Pharmaceutical Biotech Brochure

New York | Los Angeles | Washington, DC | São Paulo | Frankfurt
London | Munich | Beijing | Hong Kong | Seoul | Singapore | Tokyo



Practice Overview

Milbank lawyers have been lead counsel on over 20 complex pharmaceutical, biotechnology, chemical and medical device cases. For example, Milbank lawyers were lead counsel on multi-patent, multi-party litigation relating to the medicine Prilosec®, which at the time was the world's largest selling drug. Milbank successfully defended the Prilosec® franchise in the US in two multi-defendant trials and also coordinated worldwide litigations on the same subject matter.

Milbank's biopharma practice also has extensive experience with Hatch-Waxman litigation. Recent Hatch-Waxman cases include litigation against two generic ANDA filers for Quillivant XR®, the first and only once-daily extended release liquid medicine for ADHD, as well as cases relating to specialty sublingual delivery technologies in products for the treatment of opioid addiction (Zubsolv®), breakthrough cancer pain (Abstral®) and insomnia (Edluar®).

Other examples include litigations involving (1) rubber additives for tires, (2) human papillomavirus tests, (3) formulations for administration of antidepressant, (4) treatment for impaired glucose tolerance and diabetes, (5) biotechnology and pharmaceuticals for cancer treatments, (6) formulations for medicines used for sleeping disorders, (7) antibiotics, (8) herbicide resistant genes and plants, and (9) several medical device cases.


Errol Taylor heads Milbank's biopharma practice and is recognized as one of the world's leading pharmaceutical litigators by numerous publications including *Chambers USA*, *PLC Which Lawyers?*, *Super Lawyers*, and *IAM Magazine*, which selected Mr. Taylor as one of the 250 top patent litigators in the world and in the top tier of New York patent lawyers.

Michael Nolan heads Milbank's widely recognized International Arbitration practice with a focus on transnational litigation, and he is consistently recognized as a leading International Arbitration practitioner by *Chambers USA*, *Legal 500*, *Euromoney* and *Super Lawyers*. He leads the practice in representing clients in US federal and state courts and before arbitral tribunals in all manner of complex disputes including intellectual property, general commercial, securities, tax and insolvency cases across various industries, including pharmaceuticals.

Milbank biopharma lawyers manage the intersection of pharma patent litigation and FDA and FTC issues, and negotiate numerous complex settlements in Hatch-Waxman cases.

Chris Gaspar and Fred Zullo are partners in the pharmaceutical, biotechnology, chemical and medical device practice with many high-profile IP litigation victories and years of transactional IP experience representing Fortune 50 and Fortune 100 companies. Mr. Taylor and Mr. Gaspar are acknowledged as leading attorneys in the *Managing Intellectual Property* Guide in 2014 and 2015.

Milbank's intellectual property practice group provides comprehensive and sophisticated IP service. We offer a comprehensive approach to dispute resolution and problem-solving. In addition to litigation, Milbank provides pre-litigation counselling, infringement and validity opinions, transactional IP representation, patent prosecution, and assistance with alternative dispute resolution and settlement negotiations.



“... is praised for its “strategic nous in adversarial situations, combined with deep technology and transactional expertise” as well as “a sterling reputation for its pharmaceuticals work, particularly in contentious scenarios.””

— ***IAM LICENSING 250 – THE WORLD'S LEADING PATENT & TECHNOLOGY LICENSING LAWYERS***

Recent Pharmaceutical, Chemical, Biotechnology & Medical Device Cases:

- Secured a victory of unprecedented size in a commercial arbitration involving a multi-billion dollar genetic engineering technology on behalf of **Bayer CropScience**. Milbank had represented Bayer in a dispute administered by the ICC against Dow AgroSciences, a former licensee, who violated the terms of its French law-governed license and committed acts of infringement by impermissibly using our client's proprietary technology – an herbicide resistant gene. Milbank successfully obtained an arbitral award on behalf of Bayer of more than \$456 million dollars for breach of contract and patent infringement in October 2015. Milbank then won a hard-fought US district court confirmation of the award in 2016. On March 1, 2017, The Federal Circuit upheld the district court's confirmation of the arbitration award to Bayer, again rejecting Dow's claims that the award was unmerited. On December 4, 2017, the U.S. Supreme Court denied Dow's petition for certiorari, putting a final end to a dispute that had begun in 2012. With Milbank's help, Bayer successfully opposed Dow's petition for certiorari.
- Secured on behalf of plaintiffs, **Orexo AB** and **Orexo US, Inc.**, an important victory in the US Court of Appeals for the Federal Circuit in a patent infringement lawsuit against Actavis relating to patents that cover Orexo's flagship Zubsolv® product. Zubsolv® is a sublingual tablet that is used to treat adults who are addicted to opioid drugs (either prescription or illegal). Actavis advised Orexo that it filed an Abbreviated New Drug Applications with the FDA seeking approval to market a generic versions of Zubsolv® before the expiration of patents that cover the product and its method of use. As a result of the Court decision, Orexo has secured patent protection for Zubsolv® through patent expiration in 2032.
- Secured an important victory in the US Court of Appeals for the Federal Circuit for **Tris Pharma, Inc.**, in a lawsuit against Actavis on patents that cover Tris's Quillivant XR® product. Quillivant XR® is the first liquid long-acting treatment for ADHD (Attention Deficit and Hyperactivity Disorder). The appellate court vacated the district court's opinion invalidating three Tris patents. The patents protect Quillivant XR® through 2031. In 2014, Actavis advised Tris that it was seeking FDA approval to immediately market a generic version of Quillivant XR®. Tris filed suit and a bench trial was completed in February 2017. In September 2017, the court held that the asserted patents were invalid. Tris appealed portions of the district court judgment relating to three patents. On November 20, 2018, the appellate court vacated the district court's decision.
- Representing plaintiffs, **Orexo AB** and **Orexo US, Inc.**, in a patent infringement lawsuit against Actavis and affiliated and parent companies relating to Actavis's generic versions of Suboxone and Subutex, medications used to treat opioid addiction. The asserted patent, U.S. Patent No. 8,454,996, was the subject of earlier litigation between Orexo and Actavis, and was held valid in that earlier lawsuit.



“This compact but highly effective team offers a full IP service, including patent applications prosecution, transactional work and litigation in all rights.”


— **Chambers USA**

“The ‘extremely responsive’ [Chris] Gaspar ‘brings a lot of background knowledge to every case and gives you a fair read on whether something should be settled or fought’. In addition, he is ‘technically excellent’ and ‘goes above and beyond the brief to assist.’”

— **IAM Patent**

- Represented plaintiff, **Orexo AB**, in a patent infringement lawsuit against Actavis relating to patents that cover Abstral®, a sublingual tablet that is used to treat break-through cancer pain. In December 2014, Actavis advised Orexo that it filed an Abbreviated New Drug Application with the FDA seeking approval to market a generic version of Abstral® before the expiration of patents that cover the product and its method of use. Orexo filed suit in the US District Court for the District of New Jersey. The case settled in October 2015 on terms favorable to Orexo.
- Represented **Merck & Co.** in its litigation with Gilead Sciences Inc. in the US District Court for the District of Delaware regarding Merck's patents covering hepatitis C medications.
- Represented **multinational pharmaceutical and biologics companies** in two multi-party, multi-patent trials in the Southern District of New York against eight generic pharmaceutical companies involving patents on a widely used anti-ulcer medicine and continued representation on related antitrust and unfair competition claims. Subsequently represented both companies on multiple related appeals and in damages actions against infringing defendants.
- Successful representation of a **multinational pharmaceutical and biologics company** in a pharmaceutical patent litigation trial in the Southern District of New York seeking damages from Andrx for its manufacture of a generic form of a blockbuster drug.
- Represented **Orexo** against two generic companies in ANDA litigation involving two patents relating to zolpidem tartrate sublingual tablets for the treatment of insomnia.
- Represented **The Sun Products Corporation** in patent litigation initiated by Big 3 Packaging, LLC and Cot'n Wash, Inc. relating to a patent for unit-dose laundry detergents of well-known brands. Milbank secured a favorable ruling on appeal in favor of its client.
- Represented **SI Group, Inc.**, in the International Trade Commission (ITC) against multiple Chinese chemical respondents for trade secret misappropriation relating to rubber additives for tires.
- Represented **Digene** in the Western District of Wisconsin against Third Wave for infringement of a patent directed to a type of high-risk HPV, which causes cervical cancer.
- Represented **Invitrogen Corporation** against Clontech before the Federal Circuit regarding validity of Invitrogen's three patents for genetically engineered reverse transcriptase enzyme—a critical scientific tool used for cloning DNA in laboratories worldwide.
- Represented **a major agrochemicals company**, along with co-plaintiff, a leading chemical company, in two patent infringement actions filed in the US District Court for the Middle District of North Carolina against two international agricultural generics, regarding manufacture and use of insecticide as a termiticide.
- Represented **a major agrochemicals company** in a patent infringement action against a generic agribusiness regarding its fungicide products marketed primarily to golf courses.

“Milbank . . . fields a sterling [IP] practice with a compact core team . . . The group demonstrates excellent sectorial breadth . . .”
 — **Legal 500 USA**



- Represented a **major agrochemicals company** in its defense of a declaratory judgment action of invalidity and non infringement of its patents related to recombinant plants expressing insecticidal crystal proteins.
- Represented a **major agrochemicals company** in its defense of a declaratory judgment action by a generic supplier of crop-protection products for patent infringement, tortious interference with contract, and unfair and deceptive trade practices under State, Federal, and Common Law. Our client countersued for patent infringement, misappropriation of trade secrets and unfair competition.
- Represented **Foot Levelers, Inc.**, the defendant in a qui tam action brought by Unique Product Solutions in the Northern District of Ohio for patent false marking under 35 USC 292 (b).
- Represented **Tyco Healthcare's** Ludlow Corp. and Kendall divisions in infringement litigation initiated by Conmed Corp. in Syracuse, New York concerning ECG electrodes.
- Represented **Tyco Healthcare's** Valleylab division in infringement litigation concerning electrosurgical electrodes.
- Represented **Tyco's** Radionics unit in defense of an infringement suit filed by Oratec Interventions in the field of back pain treatment catheters.
- Represented a **major biotechnology companies** regarding licenses for Cabilly patents involving the manufacture of human antibodies in cell cultures.
- Represented a **multinational pharmaceutical company** regarding license for erythropoietin related drugs produced by recombinant DNA technology in cell cultures.
- Represented a **multinational pharmaceutical company** regarding freedom to operate novel method for producing certain erythropoietin related drugs.
- Represented a **private medical device company** in patent and trade secret case relating to stents and stent grafts for aneurysms.
- Represented a **medical device innovator** on patent relating to aortic stents.
- Licensing for independent inventor relating to EWSL (Extracorporeal Shock Wave Lithotripsy).
- Represented alleged infringer on patents relating to MRI Technology.
- Represented alleged infringer at trial and on appeal on patents relating to Guide Wires for Balloon Catheters.
- Represented alleged infringer on patents relating to Urinary Catheters.
- Represented client successfully in patent-infringement litigation relating to prostate treatment device.

“[Errol Taylor] never comes on too strong and has a certain calm demeanour and elegance in the courtroom. The objections he raises are brilliant.’ The pharmaceutical sector is his main proving ground, and he regularly links up with Fredrick Zullo to dispatch cases with a powerful one-two punch.”

— *IAM Patent*

“[Milbank is] a ‘top-tier corporate and litigation shop which does outstanding work in the patent area’.”

— *IAM Patent*

Key Contacts

To discuss our capabilities, please visit our website at www.milbank.com or contact any of the attorneys listed.

New York

55 Hudson Yards, New York, NY 10001

PARTNERS

| | | |
|-----------------------|---------------------|-----------------|
| Errol B. Taylor | etaylor@milbank.com | +1-212-530-5545 |
| Michael D. Nolan | mnolan@milbank.com | +1-202-835-7524 |
| Christopher J. Gaspar | cgaspar@milbank.com | +1-212-530-5019 |

SPECIAL COUNSEL

| | | |
|----------------------|----------------------|-----------------|
| Nathaniel T. Browand | nbrowand@milbank.com | +1-212-530-5096 |
|----------------------|----------------------|-----------------|

ASSOCIATES

| | | |
|---------------------|----------------------|-----------------|
| Venus Allahyarzadeh | vallahya@milbank.com | +1-212-530-5133 |
| Anna Brook | abrook@milbank.com | +1-212-530-5607 |
| Sean L. Hyberg | shyberg@milbank.com | +1-212-530-5033 |
| Jacob Jou | jjou@milbank.com | +1-212-530-5180 |
| Kyanna Lewis | klewis2@milbank.com | +1-212-530-5427 |
| Jordan Markham | jmarkham@milbank.com | +1-212-530-5175 |
| Javier Ramos | jramos@milbank.com | +1-202-835-7507 |

“Not many doing this work have [Chris Gaspar’s] intellectual prowess. He’s an extraordinarily clear communicator who is always in touch with his audience.”

— *IAM Patent*

“[Milbank] attracts and retains some of the best lawyers in the business”

— *IAM Patent*

“Nationally, its litigators have been pushing hard on the most gruelling competitor-on-competitor dogfights; winning in cases that go the distance has become a real trend.”

— *IAM Patent*



Errol B. Taylor

Partner

etaylor@milbank.com

T: +1.212.530. 5545

55 Hudson Yards

New York, NY 10001-2163



Errol Taylor is a partner in the New York office of Milbank LLP and leads the firm's biopharma patent litigation practice. Mr. Taylor has been a partner since 2003. Mr. Taylor focuses mainly on representing research pharmaceutical and biotechnology companies in patent litigation and related counseling. Mr. Taylor has served as an advisor on IP litigation and development strategy for pharmaceutical companies of all sizes. He has particular expertise in IP matters involving FDA regulatory approvals of new drugs, including Hatch-Waxman Act cases. Mr. Taylor has been lead trial counsel in numerous multi-party, multinational cases involving some of the world's most prescribed medicines.

Primary Focus & Experience

Mr. Taylor has given lectures in the areas of pharmaceutical litigation, strategy and advice, IP damages and injunctions to various legal professional associations, including The American Bar Association; American Intellectual Property Law Association; Federal Circuit Bar Association; Pharmaceutical Research Manufacturers Association; National Bar Association; New York Intellectual Property Law Association; and The Association of the Bar for the City of New York.

His litigations include:

- lead counsel in seven-month multiparty trial and appeals involving the world's largest selling drug
- lead counsel for biotechnology company in litigation involving human papillomavirus tests
- lead counsel in litigation involving formulations for administration of antidepressant
- lead counsel in trial and appeals regarding treatment for impaired glucose tolerance and diabetes
- counsel for chemical company in litigation regarding polyester fiber technology
- counsel for biotechnology company in ITC litigation regarding cancer treatment

Recognition & Accomplishments

Mr. Taylor has been recognized as one of the world's leading pharmaceutical attorneys by numerous publications and journals, among them: *Chambers USA*, *PLC Which Lawyers?*, *Super Lawyers*, and *IAM Magazine*, which selected him as one of the 250 top patent litigators in the world and in the first tier of New York lawyers. *Lawdragon* has named Mr. Taylor in its 2018 guide of the 500 Leading Lawyers in America. In 2003, he was selected by *The National Law Journal* as one of the nation's top trial lawyers.

Mr. Taylor received an honorary Ph.D. degree from the State University of New York at Oswego in 2006, and was President of the Board of Trustees of the Chapin School in Princeton, NJ.

Education

New York Law School, J.D.

State University of New York at Oswego, B.A.

Admissions

New York

US Supreme Court

US District Court for the Southern District of New York

US District Court for the District of Columbia

US Patent and Trademark Office



Michael D. Nolan

Partner

mnolan@milbank.com

T: +1.202.835.7524

55 Hudson Yards

New York, NY 10001-2163



Michael D. Nolan is a partner in the Washington, DC office of Milbank LLP and a member of the firm’s Litigation & Arbitration Group.

Primary Focus & Experience

Partner since 1998, Mr. Nolan is a broadly experienced litigator with particular expertise in crossborder disputes. He has served as counsel or arbitrator in commercial cases under most major arbitration rules. He has also represented both investors and states in arbitrations pursuant to bilateral and multilateral treaties.

Mr. Nolan’s cases have involved financial and securities transactions; commercial contracts; energy, infrastructure and mining; telecommunications and satellites; real estate and construction; hospitality and gaming; insurance; taxation; patents, trademarks and intellectual property licenses; and bankruptcy and financial restructuring.

He also has represented companies and states in connection with court proceedings involving sovereign immunity, act of state, and the recognition and enforcement of foreign judicial decisions and international arbitration awards.

Mr. Nolan has substantial experience with the US Foreign Corrupt Practices Act, other anti-bribery laws and sanctions programs. He has developed and implemented anti-corruption programs for companies and financial services firms.

Recognition & Accomplishment

Mr. Nolan is consistently recognized as a leading International Arbitration practitioner by *Chambers USA*, *Chambers Global*, *Legal 500*, *Benchmark Litigation*, *Euromoney* and *Super Lawyers*. He was named *Benchmark Litigation’s* “International Arbitration Lawyer of the Year” in 2018.

Mr. Nolan writes and lectures about litigation and arbitration and co-authored the *Oxford University Press* “Reports of Overseas Private Investment Corporation Determination”, a two volume publication addressing claims determination by the US Political Risk Insurance Agency, OPIC.

Mr. Nolan serves as General Counsel of the Intellectual Property Owners Association, the leading trade association for owners of patents, trademarks, copyrights and trade secrets. He also teaches international commercial arbitration as an adjunct professor at the Georgetown University Law Center.

Mr. Nolan is a member of the International Advisory Committee of the American Arbitration Association, the Users Council of the Singapore International Arbitration Centre, the ICSID panel of arbitrators, and the British Virgin Islands International Arbitration Centre panel of arbitrators, as well as a fellow of the Chartered Institute of Arbitrators.

Education

University of Chicago, J.D.

Harvard University, A.B.

Admissions

District of Columbia

New York

US Court of Appeals for the Second Circuit

US District Court for the Eastern District of New York

US District Court for the Southern District of New York



Christopher J. Gaspar

Partner

cgaspar@milbank.com

T: +1.212.530.5019

55 Hudson Yards

New York, NY 10001-2163



Chris Gaspar is a partner in the New York office of Milbank LLP and a member of the firm's Litigation & Arbitration Group, with a focus on intellectual property.

Primary Focus & Experience

Mr. Gaspar's intellectual property litigation and counseling practice includes a wide range of technologies and products in the electrical, semiconductor, computer, financial-services, and medical-device fields. He has considerable experience in every substantial aspect of US district court, appellate court, International Trade Commission, and state court practice in intellectual property litigation, including patents, copyrights, and trademarks. He has served as lead counsel to industry-leading companies, as well as small start-ups.

As an attorney registered to practice before the US Patent and Trademark Office, Mr. Gaspar has written and prosecuted patent applications for a wide variety of technologies including grid computing, digital-signal processing, and memory mapping and optimization techniques. He also has negotiated and prepared numerous license agreements for intellectual property, and counsels clients on a wide array of intellectual property issues arising in M&A and financial-restructuring transactions. He also has obtained copyrights and trademarks, and counseled on protection of trade secrets, in a wide variety of industries.

Mr. Gaspar is an active member of the Intellectual Property Owners Association, the American Intellectual Property Law Association, and the New York Intellectual Property Law Association. Before law school, Mr. Gaspar was an engineer for Boeing Commercial Airplanes designing flight-control and autopilot computer systems for the 777.

Recognition & Accomplishment

Mr. Gaspar has been recognized by Benchmark Litigation as one of the leading lawyers in America for intellectual property. He has been ranked each year as a "Patent Star" in the *Managing Intellectual Property* IP Star rankings, and has repeatedly been ranked in the Silver Band as a leading practitioner by *IAM1000*. Mr. Gaspar is also recognized by *Legal 500* in the area of Patent Litigation (Full Coverage).

Mr. Gaspar is a frequent lecturer on IP and patent law, including invited speeches for the American Intellectual Property Law Association, Intellectual Property Owners Association, Association of the Bar of the City of New York, the US Patent and Trademark Office, and others. His articles have been published in the *American Intellectual Property Law Quarterly Journal*, *New York Law Journal*, *Intellectual Property Today*, and elsewhere.

Education

University of Iowa, J.D.

Iowa State University, B.S., Aerospace Engineering

Admissions

New York

District of Columbia

Missouri

US Supreme Court

US Court of Appeals for the Federal Circuit

US Court of Appeals for the Fifth Circuit

US District Court for the Southern District of New York

US District Court for the District of Colorado

US District Court for the Western District of Missouri



Nathaniel T. Browand

Special Counsel

nbrowand@milbank.com

T: +1.212.530.5096

55 Hudson Yards

New York, NY 10001-2163



Nathaniel T. Browand is special counsel in the New York office of Milbank LLP and a member of the firm’s Litigation & Arbitration Group, with a focus in intellectual property.

Primary Focus & Experience

Mr. Browand concentrates his practice on intellectual property law, with particular emphases in intellectual property litigation, transactional work, and counseling. He has extensive experience litigating all phases of patent and other intellectual property cases before US district courts and the International Trade Commission. He also serves as lead counsel in *inter partes* review and post grant review proceedings before the Patent Trial and Appeal Board (PTAB). He often represents clients in an array of complex technologies, including computer software, telecommunications, networking, semiconductors, image processing, and chemical manufacturing processes.

In addition to contested disputes, Mr. Browand has substantial experience advising on the intellectual property and technology aspects of mergers and acquisitions, financings, and other corporate transactions. He analyzes and negotiates licenses, services agreements, and other technology arrangements. He counsels clients in connection with transactions involving significant intellectual property assets and advises on trademark, copyright, and trade secret matters.

Recognition & Accomplishments

In 2018, Mr. Browand was recognized as a “Rising Star- United States” in *Managing Intellectual Property’s* IP Star rankings.

Mr. Browand has authored or co-authored articles on patent issues appearing in the *National Law Journal*, the *New York Law Journal* and *Law360*. He is currently a member of the Litigation Committee of the Intellectual Property Owners Association.

Mr. Browand received his B.A. from Wesleyan University and his J.D. from Boston College Law School, where he was managing editor of the *Boston College Environmental Affairs Law Review*.

Education

Boston College, J.D.

Wesleyan University, B.A., Physics

Wesleyan University, B.A., Philosophy

Admissions

New York

US Court of Appeals for the Federal Circuit

US Court of Appeals for the Second Circuit

US District Court for the Eastern District of New York

US District Court for the Southern District of New York

US Patent and Trademark Office



Venus Allahyarzadeh

Associate

vallahyarzadeh@milbank.com

T: +1.212.530.5133

55 Hudson Yards

New York, NY 10001-2163



Venus Allahyarzadeh is an associate in the New York office of Milbank LLP and a member of the firm’s Intellectual Property Practice Group.

Primary Focus & Experience

Venus is a litigator with a focus on patent litigation in district court, including trial work. She has experience with motion practice, expert report and testimony preparation, and has been to trial in a patent case. She also has an extensive background as a scientific researcher.

Recognition & Accomplishment

Venus received her J.D. from New York Law School, *cum laude*, where she was an associate fellow for the Innovation Center for Law & Technology. She received her M.S. in molecular and microbiology from San Jose State University. She earned her B.S. in molecular biology from the University of California, where she was a member of the Global Medical Brigades. Venus served as a judicial intern for the Honorable Judge Joel H. Slomsky in the United States District Court for the Eastern District of Pennsylvania.

Education

New York Law School, J.D.
*San Jose State University, M.S.,
Biological Sciences: Molecular Biology
and Microbiology*
*University of California, Santa Cruz,
B.S., Molecular, Cellular and
Development Biology*

Admissions

New York



Anna Brook

Associate

abrook@milbank.com

T: +1.212.530.5607

55 Hudson Yards

New York, NY 10001-2163



Anna Brook is an associate in the New York office of Milbank LLP and a member of the firm’s Intellectual Property Practice Group. Ms. Brook’s practice focuses on pharmaceutical patent litigation and related counseling.

Primary Focus & Experience

Ms. Brook concentrates her practice on pharmaceutical patent litigation. She worked on multiple complex litigations under the Hatch-Waxman Act, in addition to appeals to the Federal Circuit. As some examples, Ms. Brook represented clients in patent cases relating to medicines for the treatment of opioid addiction, attention deficit and hyperactivity disorder, heartburn, and insomnia.

Ms. Brook has experience advising on intellectual property issues that arise in corporate and financial transactions, as well as analyzing and negotiating technology license agreements. She has advised clients on patent prosecution and trademark matters.

Recognition & Accomplishment

Ms. Brook received a B.S.E., *summa cum laude*, from Cooper Union. She received her J.D. from Harvard Law School, where she was editor-in-chief of the *Harvard Law Record*.

Ms. Brook has co-authored articles on patent issues, including “Focusing Only on Active Ingredient Patents Ignores Case Law Success Rates,” published in *BNA’s Pharmaceutical Law & Industry Report*, “Was the Concern That KSR Was a Game-Changer Justified? Not for Chemical Cases Before the Federal Circuit,” published in *BNA’s Patent, Trademark & Copyright Journal* and also in *BNA’s Pharmaceutical Law & Industry Report* and “eBay and Preliminary Injunctions,” published in *The National Law Journal*.

Education

Harvard University, J.D.

Cooper Union, B.S., Engineering

Admissions

New York

US Court of Appeals for the Federal Circuit

US District Court for the Eastern District of New York

US District Court for the Southern District of New York



Sean L. Hyberg

Associate

shyberg@milbank.com

T: +1-212-530-5033

55 Hudson Yards

New York, NY 10001-2163



Sean Hyberg is an associate in the New York office of Milbank LLP and a member of the firm’s Intellectual Property Practice Group.

Primary Focus & Experience

Mr. Hyberg’s practice focuses on intellectual property law. His experience includes patent litigation in both the International Trade Commission and the US district courts.

Before joining Milbank, Mr. Hyberg was an associate in the intellectual property law firm Fitzpatrick, Cella, Harper & Scinto.

Recognition & Accomplishment

Mr. Hyberg received his J.D. from George Washington University Law School, where he was an Articles Editor for the *American Intellectual Property Law Association Quarterly Journal*. Also during law school, Mr. Hyberg served as a judicial intern for the Honorable Judge Kathleen M. O’Malley on the United States Court of Appeals for the Federal Circuit.

Education

George Washington University, J.D.

Duke University, B.S.E., Mechanical Engineering

Admissions

New York

Milbank

Jacob K. Jou

Associate

jjou@milbank.com

T: +1.212.530.5180

55 Hudson Yards

New York, NY 10001-2163



Jacob K. Jou is an associate in the New York office of Milbank LLP and a member of the firm's Litigation & Arbitration Group.

Primary Focus & Experience

Mr. Jou's practice focuses on commercial litigation, intellectual property law, and tax controversy. He has also represented clients in a variety of bankruptcy matters.

Mr. Jou has handled pro bono matters for the New York Civil Liberties Union and Lambda Legal.

Recognition & Accomplishment

Mr. Jou is a graduate of Harvard Law School, where he served as an executive editor of the *Harvard Civil Rights–Civil Liberties Law Review*, and Yale College, where he received the "George Hume Prize in Ethics, Politics, and Economics".

Prior to joining Milbank, he interned in the Enforcement Division of the US Securities and Exchange Commission.

Education

Harvard University, J.D.

Yale College, B.A.

Admissions

New York

US Court of Appeals for the Federal Circuit

US District Court for the Eastern District of New York

US District Court for the Southern District of New York



Kyanna Lewis Sabanoglu

Associate

Klewis2@milbank.com

T: +1.212.530.5427

55 Hudson Yards

New York, NY 10001-2163



Kyanna Lewis Sabanoglu is an associate in the New York office of Milbank LLP and a member of the firm’s Intellectual Property Practice Group. Ms. Lewis’s practice focuses on pharmaceutical patent litigation. She has worked on several complex litigations under the Hatch-Waxman Act, in addition to appeals to the Federal Circuit.

Primary Focus & Experience

Ms. Lewis Sabanoglu’s practice focuses on patent litigation. She has litigated and tried several complex patent infringement actions, including jury actions. Ms. Lewis Sabanoglu has also worked on appeals to the Federal Circuit and has helped to secure positive judgements on behalf of her clients.

Recognition & Accomplishments

Ms. Lewis Sabanoglu graduated *cum laude* from Benjamin N. Cardozo School of Law with a concentration in Intellectual Property. While in law school, she served as Submissions Editor for the *Cardozo Law Review* and as a research assistant for Professor Myriam Gilles.

Education

Benjamin N. Cardozo, J.D.
Franklin & Marshall College, B.A.

Admissions

New York
US District Court for the Eastern District of New York
US District Court for the Southern District of New York
US Court of Appeals for the Federal Circuit

Milbank

Jordan P. Markham

Associate

jmarkham@milbank.com

T: +1.212.530. 5175

55 Hudson Yards

New York, NY 10001-2163



Jordan P. Markham is an associate in the New York office of Milbank LLP and a member of the firm's Intellectual Property Group.

Primary Focus & Experience

Mr. Markham's practice focuses on patent litigation, prosecution and counseling in matters of infringement, validity and freedom to operate. He also has experience in analyzing and negotiating license agreements and addressing intellectual property issues in corporate and finance transactions.

Recognition & Accomplishment

Prior to joining Milbank, Mr. Markham performed research in organic chemistry as part of his undergraduate and graduate studies, publishing in such peer-reviewed journals as the *Journal of the American Chemical Society* and *Organic Letters*.

Education

New York University, J.D.

UC at Berkeley, M.S.

State University of New York at Buffalo, B.S.

Admissions

New York

US District Court for the Southern District of New York

US District Court for the Eastern District of New York

US Patent Office

US Court of Appeals for the Federal Circuit

Milbank

Javier J. Ramos

Associate

jramos@milbank.com

T: +1.202.835.7507

55 Hudson Yards

New York, NY 10001-2163



Javier J. Ramos is an associate in the Washington, DC office of Milbank LLP and a member of the firm's Intellectual Property Group.

Primary Focus & Experience

Javier's practice covers a wide range of complex intellectual property matters including copyright, patents, trademarks, and unfair competition, in both US federal courts and before international arbitration bodies, primarily in the agrochemical, biotechnology, chemical, and pharmaceutical industries.

His areas of experience include advising on intellectual property portfolio management; conducting freedom to operate assessments; litigating patent and trademark disputes; preparing and prosecuting domestic and foreign patent and trademark applications; and merger and acquisition due diligence and negotiations.

Prior to joining Milbank, Javier was a patent examiner with the United States Patent and Trademark Office (USPTO), examining in the image processing and image reproduction arts.

Recognition & Accomplishment

Mr. Ramos received a B.S. in Electrical and Computer Engineering from The Ohio State University, *cum laude*, and received a J.D. from Georgetown University Law Center, *cum laude*. He is also registered to practice before the USPTO

Education

*Georgetown University Law Center,
J.D.*

Ohio State University, B.S.

Admissions

District of Columbia

Virginia

US Patent and Trademark Office

Beijing

Unit 06, 15th Floor, Tower 2, China Central Place, 79 Jianguo Road, Chaoyang District, Beijing 100025, China
+8610-5969-2700

Frankfurt

Neue Mainzer Str. 74, 60311 Frankfurt am Main, Germany
+49-69-71914-3400

Hong Kong

30/F Alexandra House, 18 Charter Road, Central, Hong Kong
+852-2971-4888

London

10 Gresham Street, London EC2V 7JD, United Kingdom
+44-20-7615-3000

Los Angeles

2029 Century Park East, 33rd Floor, Los Angeles, CA 90067-3019
+1-424-386-4000

Munich

Maximilianstrasse 15, (Maximilianhoeefe), Munich 80539, Germany
+49-89-25559-3600

New York

55 Hudson Yards, New York, NY 10001-2163
+1-212-530-5000

São Paulo

Rua Colômbia, 325, Jardim América, São Paulo 01438-000, Brazil
+55-11-3927-7700

Seoul

Foreign Legal Consultant Office, Level 33, Three IFC, 10 Gukjegeumyung-ro, Youngdeungpo-gu, Seoul 07326, Korea
+822-6137-2600

Singapore

12 Marina Boulevard, Marina Bay Financial Centre, #36-03 Tower 3, Singapore 018982
+65-6428-2400

Tokyo

21F Midtown Tower, 9-7-1 Akasaka, Minato-ku, Tokyo 107-6221, Japan
+813-5410-2801

Washington, DC

1850 K Street, NW, Suite 1100, Washington, DC 20006
+1-202-835-7500

Milbank.com